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Abstract
Introduction: Genetic and disease-related factors give rise to a wide spectrum of glucocorticoid (GC) sensitivity in
rheumatoid arthritis (RA). In clinical practice, GC treatment is not adapted to these differences in GC sensitivity.
In vitro assessment of GC sensitivity before the start of therapy could allow more individualized GC therapy. The
aim of the study was to investigate the association between in vitro and in vivo GC sensitivity in RA.
Methods: Thirty-eight early and 37 established RA patients were prospectively studied. In vitro GC sensitivity was
assessed with dexamethasone-induced effects on interleukin-2 (IL-2) and glucocorticoid-induced leucine zipper
(GILZ) messenger RNA expression in peripheral blood mononuclear cells (PBMCs). A whole-cell dexamethasone-
binding assay was used to measure number and affinity (1/KD) of glucocorticoid receptors (GRs).
In vivo GC sensitivity was determined by measuring the disease activity score (DAS) and health assessment
questionnaire disability index (HAQ-DI) score before and after 2 weeks of standardized GC treatment.
Results: GR number was positively correlated with improvement in DAS. IL-2-EC50 and GILZ-EC50 values both had
weak near-significant correlations with clinical improvement in DAS in intramuscularly treated patients only. HAQ
responders had lower GILZ-EC50 values and higher GR number and KD.
Conclusions: Baseline cellular in vitro glucocorticoid sensitivity is modestly associated with in vivo improvement in
DAS and HAQ-DI score after GC bridging therapy in RA. Further studies are needed to evaluate whether in vitro GC
sensitivity may support the development of tailor-made GC therapy in RA.
Introduction
Rheumatoid arthritis (RA) is a common autoimmune
disorder characterized by chronic synovial inflammation,
leading to joint destructions. Based on their antiinflam-
matory properties, glucocorticoids (GCs) have an impor-
tant role in first-line treatment regimens for RA in
combination with disease-modifying antirheumatic
drugs (DMARDs). However, on administration of GCs,
a wide spectrum of clinical responses is observed with
up to 30% of patients being relatively GC resistant [1-3].
In addition, it is well known that in some patients side
effects rapidly develop during GC therapy, whereas
others tolerate GC well, independent of dose and treat-
ment duration. This indicates that GC sensitivity is
highly variable among patients.
Determinants of individual GC sensitivity include both
genetic and acquired factors. Functional polymorphisms
of the glucocorticoid receptor (GR) gene have been identi-
fied that modulate GC sensitivity [4]. Recently we found
that these polymorphisms are also associated with RA
susceptibility and disease severity [5]. Acquired, disease-
related factors include the effects of inflammation,
mediated by proinflammatory cytokines, on cellular GC
sensitivity, resulting in systemic or tissue-specific GC
resistance of immunocompetent cells at the site of
inflammation [6].
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Despite this wide variety in individual GC sensitivity,
RA patients are mostly treated with standardized sche-
dules, by using fixed GC dose and treatment duration,
inevitably leading to under- or overtreatment in subsets
of patients.
Considering the detrimental effects of prolonged syno-
vial inflammation in undertreated patients and the poten-
tial severe burden of GC side effects in overtreated
patients, it is obvious that a need exists for tools measur-
ing individual GC sensitivity, allowing more tailor-made
GC therapy.
GC binding capacity (that is, number and affinity of
GRs) has proven its potential as a possible predictor of
GC therapy outcome, as has been shown for asthma [7],
systemic lupus erythematosus (SLE) [8], and leukemia
[9]. In RA, both higher and lower GR expression levels
have been reported [10-13]. With respect to in vivo GC
therapy outcome, Huisman and co-workers [11] showed
that GR levels at baseline do not correlate with clinical
or radiologic outcome after 2 years of GC therapy. How-
ever, this outcome may have been influenced by conco-
mitant use of other antirheumatic drugs.
In addition, studies in patients with inflammatory
bowel disease [14], asthma [15], and RA [16] by using in
vitro functional assays have shown that the degree of
GC-mediated suppression of proliferation of peripheral
blood mononuclear cells (PBMCs) may predict in vivo
GC sensitivity. More recently, a diminished inhibitory
effect of GCs on PBMC proliferation in vitro was shown
in a larger cohort of GC resistant RA patients [3].
Recently, we developed in vitro bioassays to measure
individual cellular GC sensitivity [17]. In these bioassays,
dexamethasone-regulated expression of interleukin-2
(IL-2) and glucocorticoid-induced leucine zipper (GILZ)
are measured. Transrepressive effects of GC, traditionally
considered to be the predominant mechanism regulating
antiinflammatory actions of GC, are represented by the
IL-2 assay. The GILZ assay is an example of genes in
which transcription is transactivated by GCs. Originally
such genes were postulated to be responsible for the
development of GC-induced side-effects [18,19]. By using
these bioassays, a spectrum of GC sensitivity could be
demonstrated in healthy individuals.
The aim of this study was to examine whether in vitro
assessment of GC sensitivity of PBMCs, using both these
bioassays and measurement of GC binding capacity, is




This study was embedded in a multicenter randomized
clinical trial studying persons older than 18 years pre-
senting with recent-onset arthritis, the so-called tREACH
study (treatment in the Rotterdam early arthritis cohort)
[20]. The primary aim of this study is to establish the
best treatment strategy for patients with early arthritis.
Patients were included if arthritis in at least one joint
was observed by a rheumatologist, and complaints were
present for less than 12 months. With a prediction
model developed by Visser et al. [21], patients were
stratified according to their risk of having persistent ero-
sive disease after a follow-up period of 2 years (high,
intermediate, and low probability). We studied 41
patients in the high-probability group. These patients
were randomized to three different treatment strategies,
all including GC, either oral GC (15 mg prednisone/day,
two treatment arms) or intramuscular GC (single depot
of methylprednisolone, 120 mg, or triamcinolone aceto-
nide, 80 mg, one treatment arm). All tREACH patients
were naïve to GCs and DMARDs (Figure 1).
After a minimum of 1 year of follow-up, the diagnosis
of the patients was verified in medical documentation
or, if necessary, in consultation with the treating
rheumatologist.
In an independent cohort, 37 patients with established
RA and active disease (FLARE study) were recruited.
Active disease was defined as disease activity requiring
GC therapy according to the treating rheumatologists
[22]. All patients received a single intramuscular depot of
GC (methylprednisolone, 120 mg, or triamcinolone acet-
onide, 80 mg). None of the FLARE patients had used GC
in the last 3 months and were taking stable DMARD
therapy (Figure 1). As a control group, we studied healthy
laboratory employees (n = 20). None of the controls was
using a GC.
Of the 41 high-probability patients included via the
tREACH study, 38 were ultimately diagnosed as having
definite RA. In this group of early RA, two patients were
lost to follow-up, leaving 36 patients for complete analy-
sis. After randomization, oral GCs were prescribed to 22
patients, and 14 patients were given a single depot of
intramuscular GC. In the FLARE study, two patients
were lost to follow-up for logistic reasons. In 10
patients, only one of the assays could be performed due
to limited amount of PBMCs. Ultimately, 32 patients
could be evaluated for binding capacity of the GC recep-
tor, and 32 patients for the bioassay (in 27 patients, both
assays were performed). Patients lost to follow-up were
included in the baseline analysis (two patients in each
cohort).
Methods
Assessment of in vitro glucocorticoid sensitivity
In the tREACH cohort, in vitro GC sensitivity was
assessed with the GC bioassays (for logistic reasons, only
enough PBMCs were available for the GC bioassays).
In patients participating in the FLARE study, in vitro GC
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sensitivity was assessed by both the GC bioassays and GC
binding capacity.
The GC bioassays were performed as described pre-
viously [17]. In short, peripheral blood was drawn in all
patients before start of treatment by using Cell Prepara-
tion Tubes with Sodium Heparin (Becton Dickinson,
Breda, The Netherlands), allowing isolation of PBMCs.
Cells were resuspended in RPMI 1640 medium contain-
ing L-glutamine supplemented with penicillin (100 U/ml)
and streptomycin (100 μg/ml) and 10% fetal calf serum
(FCS) and precultured overnight in a 48-well plate
(Costar, Amsterdam, The Netherlands, 5.0 × 105 cells/
well in duplicate, density of 4.0 × 106/ml). A single batch
of FCS was used throughout. Before use, this batch was
analyzed for cortisol content, which was found to be
below the detection limits.
Trypan blue staining revealed the viability of isolated
cells to be greater than 95%. The next day, cells were incu-
bated with dexamethasone 0, 0.33, 1, 3.3, 10, 33, 100, and
333 nM dexamethasone and stimulated with 10 μg/ml
phytohemagglutinin (Sigma-Aldrich, Zwijndrecht, The
Netherlands). After 4 hours in the incubator, total RNA of
the cells was collected (Total RNA isolation Kit, Roche,
Almere, The Netherlands). Reverse transcription was per-
formed by using 100 ng total RNA per reaction. Quantita-
tive real-time PCR analysis was carried out on a 7900HT
Taqman machine (Applied Biosystems, Nieuwerkerk aan
den IJssel, The Netherlands), according to the manufac-
turer’s instructions. Data were analyzed by using the SDS
2.4 software (Applied Biosystems). GC-specific transactiva-
tion of the GILZ gene and transrepression of the IL-2 gene
were measured while correcting for the housekeeping
gene hypoxanthine phosphoribosyltransferase (HPRT) by
using the ΔΔCT method; primers and probes were
obtained from Biolegio, Nijmegen, The Netherlands (see
Additional File 1 Table S1). Half-maximal effective con-
centration (EC50) was calculated by using nonlinear
regression in GraphPad Prism 5.0 and used as a read-out
for in vitro GC sensitivity. The EC50 values of GILZ and
IL-2 in PBMCs were not significantly influenced by the
cellular composition (percentages lymphocytes and mono-
cytes) of the PBMCs (data not shown).
GC binding capacity was measured by using a whole-
cell dexamethasone-binding assay, as described pre-
viously, with minor modifications [23]. In brief, by using
PBMCs from the same isolation procedure, incubation
was started in a volume of 200 μl (0.5 to 2 × 106 cells)
containing [3H] dexamethasone at concentrations of 1 to
30 nM with and without a 400-fold excess of unlabeled
dexamethasone reflecting nonspecific and total binding
of [3H] dexamethasone, respectively. Two tubes without
labeled dexamethasone were incubated under the same
conditions for determination of cell number and viability
at the end of the procedure. The PBMCs were incubated





• Early arthritis ( < 1 year)# 
• No DMARDs or GC 
• Stratification, prediction model Visser21 
Baseline work-up: GC binding assay and GILZ/IL-2 bioassays + DAS/HAQ-DI 
Standardized 
treatment 
  Treatment arm C 
• SSZ,HCQ,MTX 
• Intramuscular GC 
 
Study characteristics 
Intramuscular depot of GC 
Patients on DMARDs kept stable 
Follow-up, 2 weeks : DAS/HAQ-DI 
Treatment arm A 
• SSZ,HCQ,MTX 
• Prednisone* 
Treatment arm B 
• MTX 
• Prednisone* 
Figure 1 Flow chart of the tREACH and FLARE study. The baseline work-up in tREACH patients included the GILZ/IL-2 assays. In FLARE
patients, both a GC-binding assay and GILZ/IL-2 assays could be performed. In all patients, disease activity score (DAS) was measured at baseline
and after 2 weeks of GC bridging therapy. #Only patients in the high-probability group eventually fulfilling the 1987 ACR criteria for RA were
included in the final analysis. *Prednisone is tapered according to the following schedule: weeks 1 through 4, 15 mg/day, weeks 5 and 6, 10 mg/
day; week 7 and 8, 5 mg/day; weeks 9 and 10, 2.5 mg/day. Intramuscular GCs could be either methylprednisolone, 120 mg, or triamcinolone
acetonide, 80 mg. Baseline workup and start of standardized treatment occurred on the same day. GC, glucocorticoids; HAQ-DI, health
assessment questionnaire disability index; HCQ, hydroxychloroquine; MTX, methotrexate; SSZ, sulfasalazine.
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during 1 hour at 30°C in a shaking water bath. The incu-
bation was stopped by the addition of 2 ml cold saline,
followed by centrifugation and two washing steps. Finally,
the PBMCs were resuspended in 250 μl saline. Radioac-
tivity in 200 μl of this suspension was counted in a liquid
scintillation counter. Specific binding was calculated by
subtracting nonspecific binding from total binding. EC50
values, receptor number, and ligand affinity (1/KD) were
calculated by using the nonlinear regression method
(GraphPad Prism, version 5.0; La Jolla, CA, USA).
In vivo glucocorticoid sensitivity
Trained research nurses examined patients before and
after 2 weeks of standardized GC treatment. Disease
Activity Score (DAS, 44 joints) was calculated according
to the following formula: DAS = 0.54 × √RAI + 0.065 ×
SJC44 + 0.33 × ln(ESR) + 0.007 × GH (RAI, Ritchie
Articular Index; SJC44, 44 swollen-joint count; ESR, ery-
throcyte sedimentation rate; GH, general health on a 100-
mm scale). As primary outcome, the relative decrease in
DAS (100 × ((DASbaseline - DASafter 2 weeks)/DASbaseline))
was used as an index for in vivo GC sensitivity. By using
this continuous outcome variable, a floor effect in patients
with relatively low disease activity was prevented. In addi-
tion, continuous variables represent the full information,
in contrast to (arbitrary) categoric data (that is, response
criteria). We chose a 2-week interval for follow-up in
tREACH patients to minimize the influence of the disease-
modifying effects of the other antirheumatic drugs on the
DAS. A similar follow-up period was chosen in the FLARE
study to make comparisons between the groups possible.
During the study period, the dose of DMARD(s) already
being used was not changed, and no additional anti-rheu-
matic therapy was started.
To explore further the effectiveness of GC therapy, the
impact of GC treatment on performing activities of daily
living was assessed by using the health assessment ques-
tionnaire disability index score (HAQ-DI). The HAQ-DI is
a widely used and validated tool to quantify functional dis-
ability in RA [24] and comprises questions about different
aspects of daily life. In particular, the minimal import dif-
ference (MID) in the HAQ-DI score is the smallest differ-
ence in HAQ-DI score that patients sense as a difference.
In clinical trials, the MID in HAQ-DI improvement ran-
ged from 0.22 to 0.24 [16,17]. As a result, patients
were classified as responder (HAQ-DIbaseline - HAQ-
DI2wks ≥ 0.25) or nonresponder (HAQ-DIbaseline -
HAQ-DI2wks < 0.25).
Glucocorticoid-induced side effects
We measured blood pressure and body weight before
and after 3 months of GC therapy in tREACH patients.
Furthermore, glycosylated hemoglobin (HbA1c) was
measured at baseline and after 3 months in tREACH
patients (HbA1c analyzer, type Adams A1c HA-8160,
Menarini Benelux).
Statistical analysis
Differences in continuous variables between the cohorts
were tested by using analysis of variance (ANOVA).
GILZ-EC50 values were normally distributed (Kolmo-
gorov-Smirnoff P > 0.20), whereas IL-2-EC50 was
square-root transformed, and the number of receptors
and KD were both natural logarithm transformed to nor-
malize the data. Bonferroni post hoc tests were used to
correct for multiple testing.
Pearson or Spearman correlation coefficients were
used to describe the bivariate relations between in vitro
parameters of GC sensitivity and DAS at baseline and
relative decrease in DAS.
ANOVA analysis was applied to test for differences in
in vitro parameters of GC sensitivity between HAQ
responders and nonresponders. Paired t tests or Wil-
coxon Signed Ranks Tests were used for analysis of
alterations in DAS, HAQ-DI scores, blood pressure,
body weight, and HbA1c values.
To test for potential confounders, each of the individual
in vitro parameters of GC sensitivity (that is, IL-2- and
GILZ-EC50, KD, and number of GRs) and selected covari-
ates were modeled by using linear regression (relative
decrease in DAS as the dependent variable). These
selected covariates included gender, age, and, based on
potential synergistic immunomodulating properties with
GCs, use of NSAIDs, number of DMARDs, and use of
anti-TNF-a agents.
Orally and intramuscularly treated patients were ana-
lyzed separately because of nonequivalent cumulative
dosages of GC (cumulative GC dosage: oral > intramus-
cular). We considered differences statistically significant
if P ≤ 0.05 (two-sided).
Ethical approval
All subjects signed informed consent, and the study was
approved by the medical ethics committee of the Eras-
mus Medical Center.
Results
Thirty-eight tREACH patients and 37 FLARE patients
were prospectively studied. Patients in the FLARE study
had a significantly higher disease activity at baseline, a
longer duration of disease, and a higher percentage of
erosions compared with tREACH patients. Further base-
line characteristics are summarized in Table 1.
Baseline in vitro glucocorticoid sensitivity in RA and
healthy controls
Overall, patients with early (tREACH cohort) and estab-
lished RA (FLARE cohort) had higher mean EC50 values
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in the IL-2 assay than did healthy controls (although not
statistically significant in the FLARE cohort), indicating
that RA patients needed a higher dosage of dexametha-
sone to suppress IL-2 mRNA expression in vitro. In
contrast to this, similar EC50 values were measured in
the GILZ assay (Figure 2A, C). Patients participating in
the FLARE study had a higher number of GRs com-
pared with healthy controls, while having comparable
affinity (1/KD) of the receptor (Figure 2E, F). The per-
centage of monocytes was measured in subsets of
FLARE patients and healthy controls and did not differ
significantly (mean ± SD, 24.6 ± 9.2 in FLARE patients
versus 20.9 ± 5.0 in healthy controls). Ligand affinity of
monocytes and lymphocytes did not differ significantly.
The number of glucocorticoid receptors per cell was
about threefold higher in monocytes as compared with
lymphocytes (data not shown). The maximum induction
of GILZ and repression of IL-2 tended to be lower in the
established RA cohort as compared with healthy controls
(P = 0.068 and P = 0.101, respectively) (Figure 2B, D).
No correlations were found between the DAS and
parameters of in vitro GC sensitivity. Of the variables
used to calculate the DAS, a negative association was
observed between the RAI and IL-2-EC50 (r = -0.465;
P = 0.005), but only in the early RA patients. No gender
differences were noted at the mean level of the IL-2-
EC50 and GILZ-EC50, number of GRs, or the affinity of
the receptor.
HAQ-DI sum scores before start of treatment did not
show any correlations with in vitro parameters of GC
sensitivity. Male and female individuals did not differ
significantly in HAQ-DI sum scores.
Correlation between in vitro parameters of glucocorticoid
sensitivity
GILZ-EC50 and IL-2-EC50 were positively correlated, but
only in the patients with early RA (r = 0.383; P =
0.028). In patients with established RA, the number of
GRs was inversely correlated with GILZ-EC50 and IL-2-
EC50 (r = -0.401; P = 0.042; and r = -0.462; P = 0.020
respectively). KD was also inversely correlated with
GILZ-EC50 (r = -0.413; P = 0.032), but not with IL-2-
EC50. Finally, KD and GR-number were correlated (r =
0.627; P < 0.001; see Additional File 2 Figure S2).
Pretreatment in vitro glucocorticoid sensitivity and disease
activity in RA after 2 weeks of glucocorticoid therapy
After 2 weeks of GC treatment, a significant decrease in
disease activity was measured in both orally and intra-
muscularly treated patients (ΔDASoral = 0.92; P < 0.001;
ΔDASintramuscular = 0.89; P < 0.001; and see Additional
File 3 Table S3). The interquartile range in relative
decrease in DAS was 22% and 43% in orally and intra-
muscularly treated patients, respectively, indicating
greater variability in relative decrease in DAS in the
intramuscularly treated group.
In patients treated with a single intramuscular depot of
GC (all FLARE patients and a proportion of tREACH
patients), a modest inverse relation was found between in
vitro GC sensitivity as reflected by IL-2-EC50 values and
the percentage improvement in DAS after 2 weeks (P =
0.029; Figure 3A). Similarly, near-significance was
reached for GILZ-EC50 values and the relative decrease
in DAS, but also only in intramuscularly treated patients
(P = 0.054; Figure 3B). In addition, the number of GRs
Table 1 Patient characteristics
Controls (n = 20) TREACH (n = 38) FLARE (n = 37)
Female gender, n (%) 10 (50) 25 (65.8) 25 (67.6)
Age in years, mean (SD) 31.8 (9.7) 53.3 (13.98)a 53.7 (13.40)a
Disease duration in months, median (range) - 5.4 (2-12) 73.0 (0-414)b
Presence of joint erosions, n (%) - 10 (26.3) 20 (54.1)c
Anti-CCP positive, n (%) - 30 (78.9) 24 (85.7)d
Rheumatoid factor (IgM) positive, n (%) - 31 (81.6) 27 (73.0)
DAS44 at baseline, mean (SD) - 3.05 (0.92) 3.57 (0.95)c
HAQ-DI at baseline, mean (SD) - - 1.43 (0.62)
Use of NSAID, n (%) - 25 (67.6) 19 (51.4)
Use of methotrexate, n (%) - - 22 (59.5)
Use of hydroxychloroquine, n (%) - - 11 (29.7)
Use of sulfasalazine, n (%) - - 5 (13.5)
Number of DMARDs, median (range) - - 1 (0-3)e
Use of anti-TNF-a therapy, n (%) - - 5 (13.5)
DAS44, Disease Activity Score, 44 joints; HAQ-DI, Health Assessment Questionnaire Disability Index. aP < 0.001 as compared with healthy controls; bP < 0.001 as
compared with tREACH patients; cP < 0.05; danti-CCP was not routinely analyzed; percentage is based on 28 patients with known anti-CCP status; eSeven patients
were not using any DMARD at the time of assessment.
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displayed a modest positive relation with the improve-
ment in DAS in patients with intramuscular depots of
GC, and a positive trend was observed for the KD of the
GRs (P = 0.008 and P = 0.070, respectively; Figure 3C, D).
With multiple regression, however, both the number
of GRs and KD of the receptor were significant factors
contributing to the relative decrease in DAS. The nega-
tive association between IL-2-EC50 and GILZ-EC50
Figure 2 Baseline in vitro parameters of GC sensitivity in healthy controls, tREACH, and FLARE patients. The IL-2 assay (A) and GILZ-assay (C)
were performed in both tREACH and FLARE patients (bioassays in 32 patients, GC-binding assay in 32 patients, bioassays and GC-binding assay in 27
patients; control groups for the bioassays (n = 20) and binding assay (n = 16) were not the same). As secondary outcome, IL-2 repression (B) and GILZ
induction (D) was calculated as follows: IL− 2 repression = 100× (IL2− expression, PHA) − (IL2− expression, 333nM)
(IL2− expression, PHA) GILZ induction = 100×
(GILZ− expression, 333nM)
(GILZ− expression, PHA)
The numbers of GRs (E) and the affinity of the receptor (F) were determined in FLARE patients only. EC50, half maximal effective concentration. P values
were calculated by using ANOVA and Bonferroni post hoc correction; normalized data were used where appropriate.
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values and relative decrease in DAS persisted, although
only near-significance was reached (Table 2).
Of note, in the subgroup of patients with evaluation of
GC-binding capacity (FLARE study), age and use of
NSAIDs were also independent predictors of improve-
ment of disease activity after 2 weeks of GC treatment.
Age and use of NSAIDs both had positive b coefficients,
indicating a better response with older age and use of
NSAIDs.
Pretreatment in vitro glucocorticoid sensitivity and
functional disability in RA after 2 weeks of glucocorticoid
therapy
After 2 weeks of GC treatment, a significant decrease in
HAQ-DI sum scores was measured (ΔHAQ-DI = -0.40;
P < 0.001). However, 12 of 34 patients still had to be
classified as nonresponders. Responders had lower EC50
values of GILZ and higher numbers of GRs with higher
KD (Figure 4). IL-2-EC50 values tended to be lower in
responders.
In vitro glucocorticoid sensitivity and development of
glucocorticoid-mediated metabolic side effects
The mean systolic and diastolic blood pressure of
patients was reduced at their 3-month follow-up visit
(systolic RRbaseline, 145.0 mm Hg; systolic RR3 months,
134.4 mm Hg; P = 0.005; and diastolic RRbaseline, 87.4
mm Hg; diastolic RR3 months, 82.6 mm Hg; P = 0.003).
This decrease was observed in both orally and intra-
muscularly treated patients. Body mass index did not
change significantly after 3 months (BMIbaseline, 26.9;
BMI3 months, 26.7).
Figure 3 Correlation between in vitro and in vivo glucocorticoid sensitivity in intramuscularly treated RA patients. In vivo glucocorticoid
sensitivity is presented as percentage improvement in DAS according to the following formula: 100× DAS, baseline −DAS, after 2weeks
DAS, baseline
Correlations between √IL-2-EC50 values (A), GILZ-EC50 values (B), natural logarithm of the number of GRs per cell (C), and natural logarithm of
the KD of the receptor (D) and percentage improvement DAS. R
2, square of the Pearson correlation coefficient; proportion explained variability.
Triangles (▲) represent the tREACH patients, and solid circles (●) represent FLARE patients.
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Table 2 In vitro parameters of GC sensitivity and relative decrease in DAS
Bioassays GC binding assay
b (95% CI)a P value b (95% CI)a P value
IL-2-EC50 -0.014 (-0.028-0.001) 0.058 KD 0.03 (0.014-0.046) 0.001
Age 0.005 (-0.002-0.110) 0.161 Age 0.009 (0.002-0.017) 0.020
Gender 0.128 (-0.057-0.312) 0.169 Gender 0.199 (0.013-0.385) 0.037
Use of NSAID 0.087 (-0.087-0.261) 0.316 Use of NSAID 0.212 (0.025-0.400) 0.028
Number of DMARDs 0.023 (-0.079-0.125) 0.647 Number of DMARDs 0.112 (0.004-0.221) 0.043
Use of anti-TNF-a 0.008 (-0.283-0.299) 0.955 Use of anti-TNF-a 0.222 (-0.010-0.455) 0.060
GILZ-EC50 -0.023 (-0.046-0.001) 0.062 GR number/1,000 0.027 (0.012-0.042) 0.001
Age 0.006 (-0.001-0.014) 0.079 Age 0.010 (0.002-0.018) 0.015
Gender 0.116 (-0.075-0.308) 0.225 Gender 0.017 (-0.188-0.223) 0.862
Use of NSAID 0.181 (-0.004-0.366) 0.055 Use of NSAID 0.203 (0.006-0.400) 0.044
Number of DMARDs 0.021 (-0.085-0.126) 0.695 Number of DMARDs 0.084 (-0.027-0.195) 0.132
Use of anti-TNF-a 0.023 (-0.270-0.320) 0.874 Use of anti-TNF-a 0.129 (-0.121-0.378) 0.297
In all four models, relative decrease in DAS was the dependent variable. The data represent the combined bioassays from intramuscularly treated patients with
early (n = 14) and established RA (n = 31). GILZ-EC50 and IL-2-EC50 were not associated with relative decrease in DAS in orally treated patients in recent-onset RA
(n = 22). The GC-binding assay is performed only in established RA (n = 30, all intramuscular GC). aValues represent adjusted b-coefficients and 95% confidence
intervals.
Figure 4 In vitro glucocorticoid sensitivity and improvement in HAQ-DI score in patients with established rheumatoid arthritis (FLARE
study). Boxplots (each box shows the mean and interquartiles) and outliers (●) of IL-2-EC50 (A), GILZ-EC50 (B), number of GRs (C) and KD of the
GRs (D) in HAQ-DI responders and HAQ-DI-nonresponders. Patients are defined as responders if their HAQ-DI sum scores were at least 0.25
lower after GC therapy.
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At baseline, the mean HbA1C was 5.51% (reference
range, 4.5% to 6.0%). Three patients had HbA1C values
above the upper limit of the normal range. After
3 months, the mean HbA1C was even somewhat lower
(5.31%; P = 0.016). Nine patients had a higher HbA1C,
four patients had an equal percentage of HbA1C, and 13
patients had an improvement. No relation was found
between alterations in HbA1C and blood pressure and
in vitro GC sensitivity, as measured by the bioassay.
Discussion
We examined whether in vitro GC sensitivity is asso-
ciated with the clinical response to GC treatment in RA.
Our results show that, in particular, the number of GRs
in PBMCs and the KD of the GRs correlated with in vivo
GC sensitivity, as reflected by the relative decrease in
DAS. Near-significant associations were found between
dexamethasone-mediated changes in IL-2- and GILZ-
mRNA expression levels and the relative decrease in
DAS. Similar patterns between clinically relevant
improvement in HAQ-DI sum scores and in vitro para-
meters of GC sensitivity were observed.
Remarkably, PBMCs of RA patients have a decreased
in vitro capacity for transrepression, which is most pro-
nounced in the early RA cohort. This transrepression of
proinflammatory cytokine production by (endogenous)
GC is an important mechanism to counteract the inflam-
matory response [25]. Consequently, reduced transrepres-
sion might hamper the resolution of acute inflammation,
governing the evolution into a chronic phase of inflamma-
tion, a central feature of many autoimmune diseases.
Interestingly, polymorphisms of the GR gene associated
with reduced (that is, 9b) or increased (that is, Bcll and
N363S) GC sensitivity are associated with increased
respectively decreased susceptibility to RA [5]. Next
to decreased GC sensitivity, a blunted hypothalamic-
pituitary-adrenal axis has been postulated to be part of
the pathophysiology of RA [26].
Importantly, we did not find a relation between disease
activity and in vitro GC sensitivity, suggesting that the
impaired GC sensitivity is not just due to increased levels
of proinflammatory cytokines. This is in accordance with
the study performed by Hearing and co-workers [14], who
also did not find a relation between disease activity and
in vitro GC sensitivity in inflammatory bowel disease.
In contrast to this reduced GC sensitivity at the tran-
scriptional level, we found a higher number of GRs in
patients with established RA. A large study by Schlaghecke
et al. [13] showed lower numbers of GR in RA. In con-
trast, Eggert and co-workers [10] found increased expres-
sion of GR, which dramatically decreased after long-term
GC treatment. Interestingly, the only study with longitudi-
nal data on GR expression in RA reports an increase in
GR expression over time in female RA patients, suggesting
a compensatory mechanism for the ongoing inflammatory
state [11]. In addition to this concept, the higher numbers
of GRs in our cohort might be interpreted as a counterba-
lancing mechanism for the reduced GC sensitivity. In line
with this hypothesis, we found a correlation between
higher numbers of GRs and lower EC50 values of GILZ
and IL-2.
GC exert their antiinflammatory properties via the GR.
On binding of GC to the GRs, the receptor-ligand complex
migrates to the nucleus to interact with GC-responsive
elements of target genes. During inflammation, cellular GC
sensitivity can be modulated by cytokines via effects on GR
number and affinity, GR translocation to the nucleus, inter-
action with inflammatory transcription factors (for exam-
ple, NF-B, AP-1) and expression of the GR-b splice
variant [27]. The assessment of GC-mediated gene expres-
sion, as performed in our bioassay, may have the advantage
of integrating all postreceptor downstream factors that
modulate GC sensitivity. Originally, the immunosuppres-
sive effects of GC were attributed to transrepression of
immune genes. We indeed found that IL-2 EC50 values are
moderately associated with the relative decrease in DAS.
However, in the last decade, increasing evidence has been
obtained pointing toward immunomodulating effects of
GC-activated genes [28].
In this perspective, the GILZ gene studied in our bioas-
say is of particular interest. GILZ can directly interfere
with the AP-1 complex [29] and can also inhibit NF-B
nuclear translocation and DNA binding in vitro [30].
Recently, GILZ has been demonstrated to function as an
endogenous inhibitor of chronic inflammation in a murine
model of RA [31]. In addition, GILZ transgenic mice are
less prone to develop T-helper 1-mediated colitis [32]. We
extend these observations by demonstrating that GILZ
regulation by dexamethasone in vitro might be a potential
marker for in vivo effects of GC therapy in humans.
Remarkably, the predictive value of the GILZ and IL-2
assays is found only in the intramuscularly treated
patients and not in the orally treated patients. A possible
explanation is that the higher dosage of GCs used in the
orally treated patients masks subtle differences in GC
sensitivity. This is supported by the fact that the inter-
quartile range in relative decrease in DAS was higher in
the intramuscularly treated patients. Furthermore, a lack
of compliance in orally treated patients could play a role,
whereas this problem is obviously not present in intra-
muscularly treated patients. Finally, differences in phar-
macokinetics and duration of disease could also be
causes adding to observed differences between orally and
intramuscularly treated patients.
In our group of patients with established RA, both the
number of GRs and the KD were positively correlated
with improvement in disease activity. From a biologic
point of view, higher numbers of receptors correlating
Quax et al. Arthritis Research & Therapy 2012, 14:R195
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to better response seems plausible. Indeed, GR levels
have been shown to serve as possible markers of GC-
therapy outcome in SLE and leukemia [8,9]. Conversely,
our observations concerning the KD of the GRs are in
contrast to other reports [7,33]. In this perspective, it is
important to note that higher numbers of GRs were
accompanied by lower affinity of the receptor (that is, a
higher KD) in several other conditions [7,33-37].
Whether this phenomenon truly occurs in vivo or repre-
sents an artificial correlation (because KD and GR number
are calculated from the same data) is yet unclear. Analysis
of GR number and KD separately by using different techni-
ques could possibly give more insight into this intriguing
observation. Clearly, the interpretation of binding assays
should be done with caution.
Although we did not measure serum levels of the exo-
genously administered GCs in our patients, the (average)
serum concentrations of these GCs, in the doses admini-
strated, are reported to be in the same (equipotent) range
as the GILZ and IL-2 EC50 values and the KD of the GRs,
suggesting that in vitro parameters of GC sensitivity may
reflect in vivo GC sensitivity reasonably well [38,39].
Unexpectedly, the IL-2/GILZ assay, integrating all deter-
minants of GC sensitivity up to the transcriptional level,
showed a weaker correlation with the in vivo response
than the more-upstream GR. However, GCs also have
effects that do not require gene transcription, also referred
to as nongenomic effects of GCs [40]. Also in RA, nonge-
nomic actions are important, as illustrated by rapid inhibi-
tion of leukocyte recruitment in inflamed joints after GC
administration [41]. GR levels may therefore be a better
predictor of in vivo GC effects, because both genomic and
nongenomic actions of GCs are taken into account.
Our study clearly highlights the potential of in vitro (bio)
assays as possible clinical markers for GC treatment of RA
patients. Recently it was shown that assessment of early
arthritis patients by a rheumatologist within 12 weeks was
associated with less joint destruction and a higher chance
of DMARD-free remission, as compared with patients
assessed after this so-called window of opportunity [42].
This favorable outcome of early treatment could be further
substantiated by effective (tailor-made) GC treatment in
the window of opportunity and emphasizes the need for
biomarkers of GC sensitivity before the start of GC
treatment.
However, several limitations in our study must be
addressed. A relatively weak correlation was found
between the GILZ and IL-2 assays and in vivo glucocorti-
coid sensitivity, restricting the usefulness of these assays in
the clinical context at this moment. Further, presumably
because of the restricted period of GC treatment, we
could not evaluate the potency of our bioassay and binding
assay to predict susceptibility for GC-mediated side effects.
Also, because GC sensitivity is highly tissue specific,
extrapolation of our findings to other inflammatory disor-
ders should be done with caution. As prednisone is a
pro-drug requiring reduction by 11b-HSD type 1, and
methylprednisolone and triamcinolone acetonide are
active 11-hydroxysteroids, it is possible that differences in
the cortisol-cortisone shuttle, mediated by the proinflam-
matory state, might also have influenced in vivo GC sensi-
tivity [43]. Furthermore local steroid metabolism in the
synovial cells may play a role in increasing local cortisol
and prednisolone concentration, as shown by Hardy and
co-workers [44]. Considering this tissue specificity and the
sample size of our RA cohort, validation of these in vitro
assays should be done in cohorts with both RA and other
autoimmune disorders.
Conclusions
We show that after 2 weeks of GC treatment of patients
with RA, the relative decrease in DAS in vivo is mod-
estly associated with the number and affinity of GRs.
Near-significant associations were found with EC50
values of IL-2 and GILZ. In vitro identification of hypo-
or hypersensitive subgroups of RA patients may facilitate
a more (alternatively: may facilitate individual GC ther-
apy) individual GC therapy for these particular patients
to maximize therapeutic efficacy and minimize time-
and dose-dependent side effects. Further studies evaluat-
ing the number and affinity of GRs in PBMCs at base-
line in relation to improvement in DAS are needed to
establish whether assessment of in vitro GC sensitivity
can support individualized therapeutic management of
RA patients treated with GCs.
Additional material
Additional file 1: Table S1. Primer and probe sequences for GILZ,
IL-2, and HPRT. This table gives the sequences of the primers and
probes used in the bioassay to measure messenger RNA levels of GILZ,
IL-2, and HPRT.
Additional file 2: Figure S2. Bivariate correlations between in vitro
parameters of glucocorticoid sensitivity. This figure displays how
different in vitro parameters of GC sensitivity, as measured in the
bioassay and GC-binding assay, correlate to each other.
Additional file 3: Table S3. DAS and individual measures of the DAS
in tREACH and FLARE patients. This table provides detailed information
on DAS and individual measures of the DAS in the different subsets of
studied patients, both at baseline and after 2 weeks of GC treatment.
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